Journal profile · ONCOLOGY-IMMUNOLOGY
Cancer Immunology Research
ISSN 2326-6066 · eISSN 2326-6074 · American Association for Cancer Research Inc. · UNITED STATES
Cancer Immunology Research: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 7.81; hybrid open access; median 231 days to acceptance (100 articles, last 24 months); 451 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Cancer Immunology Research is published by American Association for Cancer Research Inc. and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses and CAR-T cell therapy research, together about 46.3% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)
Cancer Immunology Research publishes outstanding original articles reporting major advances in cancer immunology that span the discipline from basic investigations in host-tumor interactions to developmental therapeutics in model systems, early translational studies in patients, and late-stage clinical trials. The journal disseminates knowledge of immunology to the cancer research community, catalyzing cross-disciplinary work that yields a deeper understanding of the host-tumor relationship, more potent cancer treatments, and improved clinical outcomes. Papers are stringently reviewed, and specific topics of interest include endogenous antitumor immunity, tumor-promoting inflammation, cancer antigens, vaccines, antibodies, cellular therapy, cytokines, immune regulation, immune suppression, immunomodulatory effects of cancer treatment, emerging technologies, and clinical investigations. The journal's special features include "Masters of Immunology"—primers by leading immunologists—and "Cancer Immunology at the Crossroads"—perspectives that highlight the intersection of immunology with other areas of cancer research and allied disciplines.
Source: LetPub
Research area (LetPub): ONCOLOGY-IMMUNOLOGY
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine19.3%
- Immunotherapy and Immune ResponsesImmunology and Microbiology14.4%
- CAR-T cell therapy researchMedicine12.6%
- Immune Cell Function and InteractionImmunology and Microbiology8.4%
- Immune cells in cancerImmunology and Microbiology7.5%
- Cancer Research and TreatmentsBiochemistry, Genetics and Molecular Biology4.1%
- Monoclonal and Polyclonal Antibodies ResearchMedicine3.9%
- T-cell and B-cell ImmunologyImmunology and Microbiology2.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Immunology | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 2 |
| Minor | Immunology | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Immunology | Zone 1 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 7.81LetPub ·
- CiteScore 2026-06
- 12.6LetPub ·
- SJR 2026-06
- 3.48LetPub ·
- SNIP 2026-06
- 1.32LetPub ·
- h-index
- 62LetPub ·
- h-index
- 174OpenAlex ·
- i10-index
- 1,386OpenAlex ·
- 2-year mean citedness
- 2.47OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 32.68%LetPub ·
Volume
- Articles per year
- 131LetPub ·
Articles by year OpenAlex count · 5,027 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 369 | 63 | 104 |
| 2025 | 451 | 79 | 828 |
| 2024 | 271 | 83 | 1,765 |
| 2023 | 234 | 93 | 2,579 |
| 2022 | 363 | 134 | 4,623 |
| 2021 | 234 | 106 | 5,645 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
231 daysMedian, submission to acceptance · P25–P75 192 days – 286 days
- Acceptance to online
- median 3 days (38 articles)
- Submission to online
- median 238 days
- Sample
- 100 articles with submission and acceptance dates (307 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- American Association for Cancer Research Inc.
- Country or region
- UNITED STATES
- Language
- English
- ISSN
- 2326-6066
- Electronic ISSN
- 2326-6074
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Cancer Immunology Research
What CAS zone is Cancer Immunology Research in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cancer Immunology Research is in Zone 1 of Medicine, and in Zone 2 of the minor category Immunology / Oncology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cancer Immunology Research?
The latest impact factor listed by LetPub is 7.81; CiteScore 12.6, h-index 174.
How long does peer review take at Cancer Immunology Research?
Based on the dates recorded on 100 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 231 days (interquartile range 192–286 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Cancer Immunology Research?
According to LetPub and DOAJ records, Cancer Immunology Research is indexed in SCIE and Scopus.
Is Cancer Immunology Research open access, and what is the APC?
Cancer Immunology Research is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .